Back

Latest Forum Topics / Alset    Last:0.021 --

Post Reply

Singapore-eDev Post Reply Rate topic
memyselfi Senior	24-Apr-2020 12:04        memyselfi About Contact  Quote this Post!
x 0   x 0  Alert Admin	ready to rumble after lunch..
Useful To Me  Not Useful To Me
memyselfi Senior	24-Apr-2020 12:03        memyselfi About Contact  Quote this Post!
x 0   x 0  Alert Admin	huat ah... ken777      ( Date: 24-Apr-2020 11:02) Posted: Wa worth more than Biolidics and Clearbridge combine. Like that this stock worth many times more le wor Daxtheman      ( Date: 24-Apr-2020 10:33) Posted: Load up. Singapore eDev might do a Biolidics. Don?t miss it. Based on independent valuation by reputable firm, it?s wholly own subsidiary is worth at least 500 million. Once they get acquired, it would bring the stock to over $0.30
Useful To Me  Not Useful To Me
dollarsense Veteran	24-Apr-2020 12:00        dollarsense About Contact  Quote this Post!
x 0   x 0  Alert Admin	watching, this one interesting soon
Useful To Me  Not Useful To Me
ken777 Veteran	24-Apr-2020 11:02        ken777 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Wa worth more than Biolidics and Clearbridge combine. Like that this stock worth many times more le wor Daxtheman      ( Date: 24-Apr-2020 10:33) Posted: Load up. Singapore eDev might do a Biolidics. Don?t miss it. Based on independent valuation by reputable firm, it?s wholly own subsidiary is worth at least 500 million. Once they get acquired, it would bring the stock to over $0.30
Useful To Me  Not Useful To Me
memyselfi Senior	24-Apr-2020 10:52        memyselfi About Contact  Quote this Post!
x 0   x 0  Alert Admin	i think the show not over... seems someone is collecting hover 49-50. see how this performs. put biolidics winning to absorb loss if any.
Useful To Me  Not Useful To Me
fenizz Member	24-Apr-2020 10:51        fenizz About Contact  Quote this Post!
x 0   x 0  Alert Admin	Bought some and keep for 6c-7c next week Newbeginner      ( Date: 24-Apr-2020 09:50) Posted: If break 6 later, i think will move to 1 cent
Useful To Me  Not Useful To Me
ruready Supreme	24-Apr-2020 10:47        ruready About Contact  Quote this Post!   Yells: "Follow the micro penny , May be this is the last train"
x 0   x 0  Alert Admin	Anyone can share the trading done by volume and price, I lazy go to see
Useful To Me  Not Useful To Me
Daxtheman Veteran	24-Apr-2020 10:42        Daxtheman About Contact  Quote this Post!
x 0   x 0  Alert Admin	Impact Biomedical?s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts This might indeed be worth the gamble. Might double and cross $0.10 easily
Useful To Me  Not Useful To Me
memyselfi Senior	24-Apr-2020 10:41        memyselfi About Contact  Quote this Post!
x 0   x 0  Alert Admin	MBS closed. now maybe can jeep in abit to enjoy the show. set stop loss at 45. good luck.
Useful To Me  Not Useful To Me
Daxtheman Veteran	24-Apr-2020 10:33        Daxtheman About Contact  Quote this Post!
x 0   x 0  Alert Admin	Load up. Singapore eDev might do a Biolidics. Don?t miss it. Based on independent valuation by reputable firm, it?s wholly own subsidiary is worth at least 500 million. Once they get acquired, it would bring the stock to over $0.30
Useful To Me  Not Useful To Me
Starwar88 Supreme	24-Apr-2020 10:13        Starwar88 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Don?t think will happen today la. Now trying to form a base at above 50. If today can close around 60, should be good enough for more upside tomorrow. Retailers will be sensitive to price movement of Biolidics and clearbridge. If these 2 move down a lot, will hinder the upside too. . Newbeginner      ( Date: 24-Apr-2020 09:50) Posted: If break 6 later, i think will move to 1 cent
Useful To Me  Not Useful To Me
wolverine23 Supreme	24-Apr-2020 10:08        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	1 cent! wow Newbeginner      ( Date: 24-Apr-2020 09:50) Posted: If break 6 later, i think will move to 1 cent
Useful To Me  Not Useful To Me
Newbeginner Veteran	24-Apr-2020 09:50        Newbeginner About Contact  Quote this Post!
x 0   x 0  Alert Admin	If break 6 later, i think will move to 1 cent
Useful To Me  Not Useful To Me
oreocookie Senior	24-Apr-2020 09:49        oreocookie About Contact  Quote this Post!
x 0   x 0  Alert Admin	Based on their Impact Bio sale, their NAV will increase to $0.08 plus....   from $0.02 plus. easywin      ( Date: 24-Apr-2020 09:46) Posted: Is that safe to short? Based on the lesson learned from Biolidics.
Useful To Me  Not Useful To Me
Newbeginner Veteran	24-Apr-2020 09:48        Newbeginner About Contact  Quote this Post!
x 0   x 0  Alert Admin	If price stay at this price then can buy some to keep. Go down to 4 series then next time 1billion valuation also nobody trust
Useful To Me  Not Useful To Me
ken777 Veteran	24-Apr-2020 09:48        ken777 About Contact  Quote this Post!
x 0   x 0  Alert Admin	This counter have not even start to run yet after the news lol Sgvale      ( Date: 24-Apr-2020 09:24) Posted: It is accredited & valued by medical professional. SeD reaping fortune johnng      ( Date: 24-Apr-2020 07:59) Posted: Another sell-on news Impact Biomedical&rsquo s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts   SINGAPORE, 23 April 2020 &ndash Singapore Exchange-listed Singapore eDevelopment Limited&rsquo s (Stock Code 40V) (&ldquo SeD&rdquo ) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical&rsquo s effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology.  The commercial assessment includes: 3F Biofragrance &ndash a key component of the Open Air Defense Initiative, Equivir - an OTC medication with broad antiviral activity, and Linebacker - a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.   This research is part of a multi-year pandemic research program conducted by Impact Biomedical&rsquo s research partner, GRDG Sciences, LLC (&ldquo GRDG&rdquo ), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA).  All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  Previous antimicrobial research was conducted at multiple independent laboratories.  The technology consists of:   &bull 3F Antiviral Biofragrance &ndash 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry.  The concept is rather than quarantine people from the virus, quarantine the virus from people.  3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET.  3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes.  The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 2 of 4     in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic.  3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.   &bull Equivir &ndash Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies.  Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.   &bull Linebacker &ndash Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA).  Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs.  Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson&rsquo s, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.   &bull Laetose - Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.   Previous research identified the Angiotensin converting enzyme 2 (&ldquo ACE2&rdquo ) as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic.  Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.      &ldquo This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed&rdquo said Mr Chan Heng Fai, Executive Chairman of SeD.    GRDG&rsquo s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, &ldquo the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives.&rdquo Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 3 of 4       Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer.  Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, &ldquo GRDG&rsquo s multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic.&rdquo   Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, &ldquo We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.   &ldquo Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending &lsquo patent cliff&rsquo crisis expected in 2024.   &ldquo Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on &lsquo difficult to achieve&rsquo or nearly impossible projects utilizing lessons learned from our previous projects.&rdquo   Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should tak
Useful To Me  Not Useful To Me
easywin Supreme	24-Apr-2020 09:46        easywin About Contact  Quote this Post!
x 0   x 0  Alert Admin	Is that safe to short? Based on the lesson learned from Biolidics.
Useful To Me  Not Useful To Me
wolverine23 Supreme	24-Apr-2020 09:24        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	Enjoy the chance to buy low for few hours. Haha!
Useful To Me  Not Useful To Me
Sgvale Supreme	24-Apr-2020 09:24        Sgvale About Contact  Quote this Post!
x 0   x 0  Alert Admin	It is accredited & valued by medical professional. SeD reaping fortune johnng      ( Date: 24-Apr-2020 07:59) Posted: Another sell-on news Impact Biomedical&rsquo s Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts   SINGAPORE, 23 April 2020 &ndash Singapore Exchange-listed Singapore eDevelopment Limited&rsquo s (Stock Code 40V) (&ldquo SeD&rdquo ) wholly owned subsidiary Impact Biomedical Inc., announced today that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical&rsquo s effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). Following encouraging COVID-19 testing results, the groundbreaking technology was independently valued by recognized intellectual property valuation and licensing firm Destum Partners, known globally for its high level of expertise and capability in independently valuing and licensing pharmaceutical technology.  The commercial assessment includes: 3F Biofragrance &ndash a key component of the Open Air Defense Initiative, Equivir - an OTC medication with broad antiviral activity, and Linebacker - a broad-spectrum universal therapeutic. Continuing development of the COVID-19 research program is underway.   This research is part of a multi-year pandemic research program conducted by Impact Biomedical&rsquo s research partner, GRDG Sciences, LLC (&ldquo GRDG&rdquo ), which covers a wide range of solutions to global health issues to adhere to the principles and initiatives established by Project Bioshield and the Biomedical Advanced Research and Development Authority (BARDA).  All three compounds were tested against a rigorous in vitro respiratory virus panel by GRDG, who utilized the non-clinical and pre-clinical services program offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  Previous antimicrobial research was conducted at multiple independent laboratories.  The technology consists of:   &bull 3F Antiviral Biofragrance &ndash 3F Antiviral Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit such as airports, containment areas, train stations, convention centers, hospitals, and ports of entry.  The concept is rather than quarantine people from the virus, quarantine the virus from people.  3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET.  3F Mosquito uses other receptor modalities than traditional mosquito repellents to effectively blind humans to mosquitoes.  The Open Air Defense Initiative was created as a solution for Event 201, a pandemic exercise conducted Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 2 of 4     in 2019 by the Johns Hopkins Center for Health Security, the World Economic Forum and the Bill and Melinda Gates Foundation. Event 201 highlighted areas where public/private partnerships are vital to respond to a severe pandemic.  3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.   &bull Equivir &ndash Equivir was created as a solution for Project Bioshield, a U.S. government program to conduct and support research and development activities for countermeasures in biological emergencies.  Equivir is a patented OTC medication that has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.   &bull Linebacker &ndash Linebacker was modeled to shadow the Panacea program created by the US Defense Advanced Research Projects Agency (DARPA).  Panacea was a research program designed to provide novel, multi-target therapeutics for unmet physiological needs.  Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson&rsquo s, multiple histotypes of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and COVID-19.   &bull Laetose - Laetose is a reduced calorie low glycemic sugar replacement created to address the rising global problem of metabolic disorders and associated conditions.   Previous research identified the Angiotensin converting enzyme 2 (&ldquo ACE2&rdquo ) as the host receptor for SARS-CoV-2, the virus causing the COVID-19 pandemic.  Molecular docking conducted by GRDG indicated that Linebacker and Equivir cause a conformational change and modulate the ACE-2 receptor and block three integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease on the ACE-2 receptor.      &ldquo This professional valuation further validates our technologies, allowing us to move to the next step of engaging in further collaborations to bring things up to speed&rdquo said Mr Chan Heng Fai, Executive Chairman of SeD.    GRDG&rsquo s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said, &ldquo the multiple strategies developed by GRDG to fight global healthcare issues including the recent COVID-19 pandemic are important advances in science to potentially save many lives.&rdquo Press Release &ndash Impact Biomedical&rsquo s Next Generation Medical Technologies Valued at $592 Million by Independent Experts   23 April 2020   Page 3 of 4       Also advising GRDG is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer.  Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, &ldquo GRDG&rsquo s multi-prong strategy to develop and validate different technologies for threats to health is a positive step forward to address many unmet medical needs including the application of evolving novel interventions to address the current Coronavirus pandemic.&rdquo   Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, &ldquo We are proud of the Impact Biomedical research team and the successful accomplishment of a 5 year research and development project focused on the identification and proving of viable biodefense countermeasures as outlined in the Pandemic and All Hazards Preparedness Act established in 2006.   &ldquo Moving ahead we are looking forward to another series of research focused on developing global viral mitigation and control technologies for scenarios such as the current COVID-19 outbreak, the development of novel antiviral therapeutics, as well as addressing solutions for the impending &lsquo patent cliff&rsquo crisis expected in 2024.   &ldquo Impact Biomedical and its research partner Global Research and Discovery Group Sciences will work with leading global policy makers to establish specially created research teams focused exclusively on &lsquo difficult to achieve&rsquo or nearly impossible projects utilizing lessons learned from our previous projects.&rdquo   Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should tak
Useful To Me  Not Useful To Me
wolverine23 Supreme	24-Apr-2020 08:40        wolverine23 About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Medical Bull 2020 !!!!!!!! = Internet Bull 2000 !!!!!!!!"
x 0   x 0  Alert Admin	Next medical bull leader building up...
Useful To Me  Not Useful To Me

                                                         First   < Newer   7721-7740 of 8048   Older>   Last